Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Genomics and Precision Health Database


Genomics & Health Impact Scan Database|Search|PHGKB
Last data update: Jan 24, 2021. (Total: 38387 Documents since 2012)
   dataset
Filtered By:
Records 1-30 (of 65 Record(s))
Query Trace: Ovarian cancer[original query]>>Evidence Synthesis[Product Type]
Publication
Initiatives to Scale Up and Expand Reach of Cancer Genomic Services Outside of Specialty Clinical Settings: A Systematic Review.
Guan Yue et al. American journal of preventive medicine 2020 Nov
Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
Guzauskas Gregory F et al. JAMA network open 2020 Oct 3(10) e2022874
Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States
GF Gusauskas et al, JAMA Network Open, October 29, 2020
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
Gonzalez Rafael et al. Gynecologic oncology 2020 Aug
Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
Simoes Correa-Galendi Julia et al. Applied health economics and health policy 2020 Jun
Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
Hurry Manjusha et al. International journal of technology assessment in health care 2020 Apr 36(2) 104-112
Mainstream consent programs for genetic counseling in cancer patients: A systematic review.
Scheinberg Tahlia et al. Asia-Pacific journal of clinical oncology 2020 Apr
The impact of communicating uncertain test results in cancer genetic counseling: A systematic mixed studies review.
Medendorp Niki M et al. Patient education and counseling 2020 Mar
A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
Sun Li, et al. JAMA oncology 2019 10 0.
Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
Li Boxuan et al. Gene 2019 Sep 714143993
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson Heidi D, et al. JAMA 2019 0 0. (7) 666-685
Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
Krassuski Lisa et al. BMC medical informatics and decision making 2019 Aug 19(1) 154
CLINGEN Actionability Report for MUTYH-Associated Polyposis - MUTYH
ClinGen Actionability Working Group
CLINGEN Actionability Report for Peutz-Jeghers Syndrome - STK11
ClinGen Actionability Working Group
CLINGEN Actionability Report for Hereditary Breast and Ovarian Cancer- BRCA1, BRCA2
ClinGen Actionability Working Group
CLINGEN Actionability Report for Ovarian cancer - RAD51C, RAD51D, BRIP1
ClinGen Actionability Working Group
CLINGEN Actionability Report for Lynch Syndrome - MLH1, MSH2, MSH6, PMS2, EPCAM
ClinGen Actionability Working Group
Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Suszynska Malwina et al. Gynecologic oncology 2019 153(2) 452-462
BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Kwon Janice S et al. Gynecologic oncology 2019 Mar 152(3) 459-464
BRCA1/2 germline missense mutations: a systematic review.
Corso Giovanni et al. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2018 27(3) 279-286
Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Müller Dirk et al. The European journal of health economics : HEPAC : health economics in prevention and care 2019 Feb
The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway.
Asphaug Lars et al. MDM policy & practice 4(1) 2381468318821103
Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
Hoskins Paul et al. Gynecologic oncology 2019 Jan
Genetic epidemiology of ovarian cancer in the 22 Arab countries: A systematic review.
Younes Nadin et al. Gene 2019 Feb 684154-164
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
Moya-Alarcón Carlota et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019 Jan
Communication about genetic testing with breast and ovarian cancer patients: a scoping review.
Jacobs Chris et al. European journal of human genetics : EJHG 2018 Dec
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation.
Ramos Marcelo Cristiano de Azevedo et al. Revista de saude publica 2018 Nov 5294
Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels.
Lee Kristy et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 Dec
A Systematic Review of How Young People Live with Inherited Disease: What Can We Learn for Li-Fraumeni Syndrome?
Forbes Shepherd Rowan et al. Journal of adolescent and young adult oncology 2018 Jul
The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
Menko Fred H et al. Familial cancer 2018 May
TOP